3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
39
Ovarian Neoplasms
32
Triple Negative Breast Neoplasms
19
Prostatic Neoplasms
17
Fallopian Tube Neoplasms
16
Neoplasm Metastasis
14
Pancreatic Neoplasms
9
Neoplasms
9
Endometrial Neoplasms
9
Carcinoma, Non-Small-Cell Lung
7
Small Cell Lung Carcinoma
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Glioma
6
Stomach Neoplasms
5
Sarcoma
5
Lung Neoplasms
5
Glioblastoma
5
Squamous Cell Carcinoma of Head and Neck
4
Metastatic Castration-resistant Prostate Cancer
4
Carcinoma, Ovarian Epithelial
4
Solid Tumors
3
Recurrence
3
Osteosarcoma
3
Neuroendocrine Tumors
3
Lymphoma, Non-Hodgkin
3
Cholangiocarcinoma
3
Urinary Bladder Neoplasms
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Prostatic Neoplasms, Castration-Resistant
2
Interventions
pembrolizumab
4
Nivolumab
4
fludarabine
3
aldesleukin
3
Ipilimumab
3
Cyclophosphamide
3
vedolizumab
2
enfortumab vedotin
2
darolutamide
2
cabozantinib
2
atezolizumab
2
Specimen Handling
2
Riluzole
2
Prednisone
2
Magnetic Resonance Spectroscopy
2
LDP-02
2
Infliximab
2
Immunoglobulin G
2
Fecal Microbiota Transplantation
2
Disulfides
2
CTLA-4 Antigen
2
CT-P13
2
Biopsy
2
relatlimab
1
prednylidene
1
palbociclib
1
olaparib
1
gallium 68 PSMA-11
1
deltacortene
1
abiraterone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urogenital Neoplasms
×
olaparib
×
1 year
×
Clear all
NCT06785636
2026-04-24
P300
Pathos AI, Inc.
Phase 1/2
Recruiting
252 enrolled